Khalil Lab
Principal Investigator: Ahmad Samir Khalil
Institution: Boston University (Boston, MA)
Primary Subfield: Synthetic Bio
Recruitment Status: ✅ Hiring Postdocs
Research Focus
Enter the text here that is the new abstract information for your application. This section must be no longer than 30 lines of text. The rapid development and deployment of therapeutic agents are critical to our ability to counteract rapidly progressing diseases. In particular, recombinant antibodies are a major tool against pathogens that, in contrast to prophylactic agents, provide immediate protection against infection and disease. In addition, antibodies are a proven antigen-binding framework that underpin many therapeutic modalities (e.g., CAR-T cells) used to treat a wide range of diseases. However, most therapeutic antibodies are produced by animal immunization—a process that suffers from significant bottlenecks in feasibility, cost, turnaround time, and scalability; furthermore, because antibodies are typically administered in protein form, both their manufacture and delivery via intravenous administration create considerable logistical challenges that limit their ability to be deployed rapidly. Collectively, existing methods to produce and deliver antibodies are unsuitable to counteract a rapidly progressing disease and, more broadly, to make antibodies the go-to solution…
Active NIH Awards
- 5R01EB038005-02: A self-amplifying RNA-based synthetic nanobody platform for next-generation therapeutics (2026)
- 1DP1EB041697-01: Direct, large-scale perturbation and mapping of protein function in human cells (2026)
- 4R01AI171100-04: Programmable benchtop bioreactors for scalable eco-evolutionary dynamics of the human microbiome (2025)
- 5R01EB029483-06: Synthetic circuit technologies for precision control and signal processing in mammalian cells (2025)
- 1R01EB038005-01: A self-amplifying RNA-based synthetic nanobody platform for next-generation therapeutics (2025)
Explore 700+ US Biology Labs on FindBioLabs.com